Jpmorgan Chase & CO Bolt Biotherapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 840 shares of BOLT stock, worth $520. This represents 0.0% of its overall portfolio holdings.
Number of Shares
840
Previous 840
-0.0%
Holding current value
$520
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding BOLT
# of Institutions
38Shares Held
23MCall Options Held
0Put Options Held
0-
Tang Capital Management LLC San Diego, CA3.81MShares$2.36 Million0.35% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.52MShares$2.18 Million0.39% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.75MShares$1.71 Million0.11% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.37MShares$1.47 Million0.0% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA1.89MShares$1.17 Million1.28% of portfolio
About Bolt Biotherapeutics, Inc.
- Ticker BOLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,641,500
- Market Cap $23.3M
- Description
- Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...